

## NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM

In 1990, Congress passed the Breast and Cervical Cancer Mortality Prevention Act, creating the CDC's *National Breast and Cervical Cancer Early Detection Program* (NBCCEDP). This program is designed to help low income, uninsured, and underserved women gain access to screening programs for early detection of breast and cervical cancers. However, as reported in a front page article of the Wall Street Journal on September 13, 2007, patients can get caught in a loophole and not get their medical care covered unless they are referred to designated providers, clinics or hospitals. Outpatient Cytopathology Center is one of the contracted NBCCEDP providers.

Diagnostic and screening services covered by NBCCEDP include clinical breast examinations, mammograms, and Pap tests. Additionally, for women whose screening outcome is abnormal, further diagnostic testing is covered. The diagnostic testing services include fine needle aspiration biopsy and surgical consultation.

### Implementation of NBCCEDP

The NBCCEDP has been implemented in all 50 states, four US territories, the District of Columbia and thirteen American Indian/Alaskan organizations. Tennessee began its outreach program in 1997.

Since 1991, NBCCEDP has helped over 2.5 million women, facilitating more than 5.8 million screening examinations and more than 2.8

million mammograms. It has resulted in the diagnosis of more than 22,000 breast cancers and 1,500 cervical cancers.

### Who qualifies for NBCCEDP?

To receive services from this program, each state may have slightly different requirements, but the following general guidelines must be fulfilled.

- A woman, age 50 years or older. For patients ages 40-49 who have a personal family history of a mother, daughter or sister with breast carcinoma or have an abnormal clinical breast examination, the age criteria may be waived.

- Have no health insurance. This means that the patient is not enrolled in Medicaid or Medicare (or the patient has Medicare Part A only), their insurance does not cover Pap tests or mammograms, or the patient cannot pay their insurance deductible.

- The patient has a low yearly income. The yearly income must meet the guidelines set by the program based on the number of people in the home (200% of the Federal Poverty Guidelines). Program staff can assist in determining whether or not a patient meets this requirement.

If a patient between 18-39 years has an abnormal clinical examination, coverage may be obtainable. The provider must call the appropriate

**NATIONAL  
BREAST AND CERVICAL  
CANCER EARLY DETECTION  
PROGRAM**

**NORTHEAST TENNESSEE  
423-979-3200  
KATHY SNYDER**

**VIRGINIA  
879-482-3468**

**NORTH CAROLINA  
919-733-4534**

**NATIONALLY  
1-888-232-4636  
WWW.CDC.GOV/CANCER/NBCCEDP**

health department and discuss the patient's findings to see if she may be enrolled in the program.

### **Who can provide care for NBCCEDP patients?**

Services are provided by local health departments, community-based health clinics and private providers. Providers must enroll in NBCCEDP in order to see patients in the program. You may elect to be either a primary screening provider, a referral provider, or both. Providers must agree to follow program guidelines and are reimbursed only for services that are listed on the fee schedule. The fee schedule follows Medicare reimbursement. To enroll, call your Breast and Cervical Cancer Early Detection Program regional coordinator at your Regional Health Office.

### **OCC and the NBCCEDP**

The Outpatient Cytopathology Center (OCC) is a NBCCEDP provider for patients who have an abnormal clinical breast examination. At our facility, we have extensive experience in performing fine needle aspiration biopsies. Fine needle aspiration biopsies can be performed on a clinically suspicious palpable breast mass, or of a mass that we can visualize with ultrasound. Both the aspiration biopsy procedure and the pathologic interpretation are performed at OCC. This aids in the accuracy of the diagnostic test as well as quicker turn around time for the results.

To schedule a patient for an appointment, please call our office and identify the patient as a participant of the NBCCEDP. The patient will be scheduled for an appointment in a timely manner. If a patient is not

already enrolled in the NBCCEDP, our staff can help facilitate their enrollment.

### **About FNA**

Fine needle aspiration biopsy is a well-tolerated minimally invasive diagnostic procedure. At OCC, we use a 25-gauge needle. This allows for adequate sampling and minimizes bleeding, bruising, and patient discomfort.

FNA is gaining popularity in the United States as a biopsy procedure for sampling breast lesions. Cells procured by FNA can be examined by light microscopy or be used for flow cytometry studies, immunohistochemical stains or molecular studies. In experienced hands, FNA can provide reliable diagnostic information that can be used to triage patients for the next appropriate medical step, be it surgical excision, pharmacologic therapy or clinical follow up.

Findings from the National Comprehensive Cancer Network (NCCN) study published in the February 1, 2006 edition of Ob. Gyn. News "demonstrated that breast cancers initially addressed by needle biopsy - either fine needle aspiration biopsy or core biopsy - ultimately entailed fewer operations of the breast, fewer total trips to surgery, and less time to completion of the diagnostic and surgical phases of cancer care."

### **Appointments**

To schedule a patient, call the Outpatient Cytopathology Center at 423-283-4734. If you have a patient with a breast mass who may qualify for the NBCCEDP, our personnel would be happy to assist you.

## **COMPANY PROFILE**

OUTPATIENT CYTOPATHOLOGY CENTER (OCC) is an independent pathology practice that specializes in performing and interpreting fine needle aspiration biopsy specimens. OCC is accredited by the College of American Pathologists. The practice was established in 1991 in Johnson City, Tennessee. Patients may be referred for aspiration biopsy of most palpable masses as well as for aspiration of non-palpable breast and thyroid masses that can be visualized by ultrasound. OCC is a participating provider with most insurance plans. Our referral area includes patients from Tennessee, Virginia, West Virginia, North Carolina, South Carolina, Kentucky and Georgia.

### **DR. ROLLINS**

**SUSAN D. ROLLINS, M.D., F.I.A.C.** is Board Certified by the American Board of Pathology in Cytopathology, and in Anatomic and Clinical Pathology. Additionally, in 1994 she was inducted as a Fellow in the International Academy of Cytology. She began her training under G. Barry Schumann, M.D. at the University of Utah School of Medicine, subsequently completed a fellowship in Cytopathology under Carlos Bedrossian, M.D. at St. Louis University School of Medicine, and has completed a fellowship in Clinical Cytopathology under Torsten Lowhagen, M.D. at the Karolinska Hospital in Stockholm, Sweden. The author of numerous articles in the field of cytopathology, Dr. Rollins also has served as a faculty member for cytopathology courses taught on a national level.

### **OFFICE**

#### **OUTPATIENT CYTOPATHOLOGY CENTER**

2400 Susannah Street Suite A  
Johnson City, TN 37601  
(423) 283-4734  
(423) 610-0963  
(423) 283-4736 fax  
fna4321@mac.com

Mailing Address:  
PO Box 2484  
Johnson City, TN 37605-2484

Monday – Friday  
8:00 am to 5:00 pm

### **DR. STASTNY**

**JANET F. STASTNY, D.O.** is Board Certified by the American Board of Pathology in Anatomic Pathology and has specialty boards in Cytopathology. She completed a pathology residency at the University of Cincinnati and subsequently a one-year fellowship in cytopathology and surgical pathology at the Virginia Commonwealth University / Medical College of Virginia. She was on the faculty at the University for 7 years specializing in gynecologic pathology and cytopathology. She has written numerous articles in the field of cytopathology and gynecologic pathology and has taught cytopathology courses at national meetings. She is currently involved on national committees dealing with current issues concerning the practice of cytology.